The Effectiveness of Henna Topical Formulation for the Prevention and Control of Hand-Foot Syndrome
Phase 2
Recruiting
- Conditions
- Condition 1: Malignant neoplasm Cancer. Condition 2: Malignant neoplasm Cancer.Malignant neoplasm of lipOther and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
- Registration Number
- IRCT20181230042179N1
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Cancer Patients Candidate for Capsitibine Therapy
Exclusion Criteria
Increased liver enzymes
increased blood creatinine
fever, and severe neutropenia that need to be stopped
Having Diabetes
Use of immunosuppressant and anti-inflammatory drugs
Having autoimmune diseases
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Side effects. Timepoint: Once a week for up to two months after intervention. Method of measurement: NCI Criteria.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does henna formulation target to prevent hand-foot syndrome in cancer patients?
How does henna compare to standard-of-care treatments like palifermin for hand-foot syndrome management?
Are there specific biomarkers that predict henna's effectiveness in mitigating capcitibine-induced hand-foot syndrome?
What are the potential adverse events associated with henna topical application in oncology settings?
What other natural compounds or combination therapies are being explored for hand-foot syndrome prevention alongside henna?